Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer

Bone

Volumn 47, Issue 5, 2010, Pages 966-974

  Ivergard M ^a   Strom O ^a,b   Borgstrom F ^a,b   Burge, R T ^c   Tosteson, A N A ^d   Kanis, J ^c  

^a i3 Innovus   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Dartmouth Medical School ^*  (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cost; FRAX; Intervention threshold; Osteopenia; Osteoporosis; QALY

Indexed keywords

RALOXIFENE;

ADULT; AGED; ALGORITHM; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SIMULATION; VERTEBRA FRACTURE;

AGED; ALGORITHMS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RALOXIFENE;

EID: 77957752481     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.07.024     Document Type: Article

References (86)

1. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22(3):465-475.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
3. Borgstrom F., Johnell O., Kanis J.A., Oden A., Sykes D., Jonsson B. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004, 22(17):1153-1165.
4. Schousboe J.T., Nyman J.A., Kane R.L., Ensrud K.E. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005, 142(9):734-741.
5. Stevenson M., Jones M.L., De Nigris E., Brewer N., Davis S., Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005, 9(22):1-160.
6. Strom O., Borgstrom F., Sen S.S., Boonen S., Haentjens P., Johnell O., et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007, 18(8):1047-1061.
7. Compston J., Cooper A., Cooper C., Francis R., Kanis J.A., Marsh D., et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50years in the UK. Maturitas 2009, 62(2):105-108.
8. Dawson-Hughes B., Tosteson A.N., Melton L.J., Baim S., Favus M.J., Khosla S., et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008, 19(4):449-458.
9. NOF, Physician's Guide to Prevention and Treatment of Osteoporosis 2003, National Osteoporosis Foundation, Washington, DC.
10. Strom O., Borgstrom F., Kleman M., McCloskey E., Oden A., Johansson H., et al. FRAX and its applications in health economics - cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 2010, 47(2):430-437.
11. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A. Case finding for the management of osteoporosis with FRAX - assessment and intervention thresholds for the UK. Osteoporos Int 2008, 19(10):1395-1408. (Erratum published 2009 Osteoporos Int 20, 499-502).
12. Tosteson A.N., Melton L.J., Dawson-Hughes B., Baim S., Favus M.J., Khosla S., et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008, 19(4):437-447.
13. J.A. Kanis, on behalf of the World Health Organization Scientific Group Assessment of osteoporosis at the primary health-care level. Technical report. WHO Collaborating Centre, University of Sheffield, UK, 2008. http://www.shef.ac.uk/FRAX/.
14. Kanis J.A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007, 18(8):1033-1046.
15. Fujiwara S., Nakamura T., Orimo H., Hosoi T., Gorai I., Oden A., et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 2008, 19(4):429-435.
16. Kanis J.A., McCloskey E., Johansson H., Strom O., Borgstrom F., Oden A. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 2008, 19(10):1395-1408. (Erratum published 2009 Osteoporos Int 20, 499-502).
17. Lippuner K., Johansson H., Kanis J.A., Rizzoli R. FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 2010, 21(3):381-389.
18. Gail M.H., Brinton L.A., Byar D.P., Corle D.K., Green S.B., Schairer C., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81(24):1879-1886.
19. Gail M.H., Costantino J.P. Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst 2001, 93(5):334-335.
20. Bondy M.L., Vogel V.G. Re: Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994, 86(17):1350.
21. Spiegelman D., Colditz G.A., Hunter D., Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994, 86(8):600-607.
22. NCCN Clinical Practice Guidelines in Oncology™, Breast Cancer Risk Reduction, v.2 2009.
23. Davids S.L., Schapira M.M., McAuliffe T.L., Nattinger A.B. Predictors of pessimistic breast cancer risk perceptions in a primary care population. J Gen Intern Med 2004, 19(4):310-315.
24. Goeree R., Blackhouse G., Adachi J. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin 2006, 22(7):1425-1436.
25. Kanis J.A., Borgstrom F., Johnell O., Oden A., Sykes D., Jonsson B. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 2005, 16(1):15-25.
26. Cauley J.A., Norton L., Lippman M.E., Eckert S., Krueger K.A., Purdie D.W., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001, 65(2):125-134.
27. Lippman M.E., Cummings S.R., Disch D.P., Mershon J.L., Dowsett S.A., Cauley J.A., et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 2006, 12(17):5242-5247.
28. Armstrong K., Chen T.M., Albert D., Randall T.C., Schwartz J.S. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol 2001, 98(6):996-1003.
29. Meadows E.S., Klein R., Rousculp M.D., Smolen L., Ohsfeldt R.L., Johnston J.A. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health 2007, 7:6.
30. Kanis J.A., Adams J., Borgstrom F., Cooper C., Jonsson B., Preedy D., et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008, 42(1):4-15.
31. Siegel J.E., Torrance G.W., Russell L.B., Luce B.R., Weinstein M.C., Gold M.R. Guidelines for pharmacoeconomic studies. Recommendations from the Panel on Cost Effectiveness in Health and Medicine. Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997, 11(2):159-168.
32. CPI, medical component, Series Id: CUUR0000SAM, Bureau of Labour Statistics (http://stats.bls.gov). [cited October 2009].
33. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19(4):385-397.
34. Strom O., Borgstrom F., Kleman M., McCloskey E., Oden A., Johansson H., Kanis J.A. FRAX and its applications in health economics-cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 2010, 47(2):430-437.
35. Costantino J.P., Gail M.H., Pee D., Anderson S., Redmond C.K., Benichou J., et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999, 91(18):1541-1548.
36. Seeman E. Alendronate and vertebral fracture risk. Mayo Clin Proc 2005, 80(9):1236. 1238; author reply 1238, 1240.
37. Kanis J.A., Johnell O., Black D.M., Downs R.W., Sarkar S., Fuerst T., et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003, 33(3):293-300.
38. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., Gennari C., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002, 87(8):3609-3617.
39. Strom O., Borgstrom F., Kanis J.A., Jonsson B. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 2009, 20(1):23-34.
40. Weycker D., Macarios D., Edelsberg J., Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006, 17(11):1645-1652.
41. Johnell O., Kanis J.A., Oden A., Sernbo I., Redlund-Johnell I., Petterson C., et al. Mortality after osteoporotic fractures. Osteoporos Int 2004, 15(1):38-42.
42. Relative survival rates by survival time 1988-2005. SEER 9 areas. Available at SEER.cancer.gov. [cited September 15, 2009].
43. Poor G., Atkinson E.J., O'Fallon W.M., Melton L.J. Determinants of reduced survival following hip fractures in men. Clin Orthop 1995, (319):260-265.
44. Kanis J., Johnell O., Odén A., Laet C.D., Jonsson B., Oglesby A. Excess Mortality after Vertebral Fracture 2002, WHO Collabortaing Centre for Metabolic Bone Diseases, Sheffield, UK.
45. Parker M.J., Anand J.K. What is the true mortality of hip fractures?. Public Health 1991, 105(6):443-446.
46. Kanis J.A., Oden A., Johnell O., De Laet C., Jonsson B., Oglesby A.K. The components of excess mortality after hip fracture. Bone 2003, 32(5):468-473.
47. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000, 11(7):556-561.
48. Vestergaard P., Rejnmark L., Mosekilde L. Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int 2007, 18(12):1583-1593.
49. Bliuc D., Nguyen N.D., Milch V.E., Nguyen T.V., Eisman J.A., Center J.R. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Jama 2009, 301(5):513-521.
50. Borgstrom F., Carlsson A., Sintonen H., Boonen S., Haentjens P., Burge R., et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006, 17(7):996-1007.
51. NICE Osteoporosis - secondary prevention including strontium ranelate: appraisal consultation document 2008, www.nice.org.uk.
52. RED BOOK. [cited February 5, 2010].
53. American Medical Association Current Procedural Terminology Fourth Edition (CPT®), Physician Fee Schedule 2008, http://www.cms.hhs.gov/PFSlookup/02_PFSSearch.asp. [cited November 3, 2009].
54. Kanis J., Brazier J., Stevenson M., Calvert W., Jones M.L. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002, 6(29):1-146.
55. U.S. Census Bureau, Current Population Survey, 2009 Annual Social and Economic Supplement, PINC-04. [cited Sept 09, 2009].
56. Labor force statistics from the current population survey. 2008, Bureau of labor statistics, http://www.bls.gov/cps/ (cited Sept. 09, 2009).
57. Lekander I., Borgstrom F., Strom O., Zethraeus N., Kanis J.A. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK - results based on the Women's Health Initiative randomised controlled trial. Bone 2008, 42(2):294-306.
58. Zethraeus N., Borgstrom F., Jonsson B., Kanis J. Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. Int J Technol Assess Health Care 2005, 21(4):433-441.
59. Peasgood T., Herrmann K., Kanis J.A., Brazier J.E. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 2009, 20(6):853-868.
60. Hanmer J., Lawrence W.F., Anderson J.P., Kaplan R.M., Fryback D.G. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006, 26(4):391-400.
61. Lidgren M., Wilking N., Jonsson B., Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res 2007, 16(6):1073-1081.
62. Oleksik A., Lips P., Dawson A., Minshall M.E., Shen W., Cooper C., et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000, 15(7):1384-1392.
63. Kanis J.A., Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int 2002, 13(10):765-767.
64. Greendale G.A., Espeland M., Slone S., Marcus R., Barrett-Connor E. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 2002, 162(6):665-672.
65. Bagger Y.Z., Tanko L.B., Alexandersen P., Hansen H.B., Mollgaard A., Ravn P., et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004, 34(4):728-735.
66. Christiansen C., Christensen M.S., Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981, 1(8218):459-461.
67. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., Cummings S.R. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995, 122(1):9-16.
68. Banks E., Beral V., Reeves G., Balkwill A., Barnes I. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. Jama 2004, 291(18):2212-2220.
69. Ström O., Landfeldt E., Robbins S., Borgström F. Adherence to treatment of osteoporosis and fracture risk: the Swedish Adherence Register Analysis (SARA). Oral presentation/poster ECCEO/IOF, Florence 2010.
70. Lee W.L., Chao H.T., Cheng M.H., Wang P.H. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas 2008, 60(2):92-107.
71. Lippuner K., Johansson H., Kanis J.A., Rizzoli R. FRAX(R) assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 2009.
72. Lippuner K., Johansson H., Kanis J.A., Rizzoli R. FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 2010, 21(3):381-389.
73. Chen Z., Maricic M., Aragaki A.K., Mouton C., Arendell L., Lopez A.M., et al. Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. Osteoporos Int 2009, 20(4):527-536.
74. Solomon D.H., Morris C., Cheng H., Cabral D., Katz J.N., Finkelstein J.S., et al. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 2005, 80(2):194-202.
75. Chen Z., Arendell L., Aickin M., Cauley J., Lewis C.E., Chlebowski R. Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer 2008, 113(5):907-915.
76. Zhang Y., Kiel D.P., Kreger B.E., Cupples L.A., Ellison R.C., Dorgan J.F., et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997, 336(9):611-617.
77. Melton L.J., Crowson C.S., O'Fallon W.M. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 1999, 9(1):29-37.
78. Surveillance, epidemiology and end results, National Cancer Institute. Incidence rates, SEER 17 areas. Available at seer.cancer.gov. 2002-2006 [cited September 15, 2009].
79. Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998, 158(6):585-593.
80. Life tables 2004, Available at http://www.cdc.gov/nchs/products/nvsr.htm. [cited September 15, 2009].
81. Douketis J.D., Kearon C., Bates S., Duku E.K., Ginsberg J.S. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. Jama 1998, 279(6):458-462.
82. Shi N., Foley K., Lenhart G., Badamgarav E. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 2009, 45(6):1084-1090.
83. Warren J.L., Brown M.L., Fay M.P., Schussler N., Potosky A.L., Riley G.F. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol 2002, 20(1):307-316.
84. Knight K.K., Wong J., Hauch O., Wygant G., Aguilar D., Ofman J.J. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health 2005, 8(3):191-200.
85. Schousboe J.T., Bauer D.C., Nyman J.A., Kane R.L., Melton L.J., Ensrud K.E. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int 2007, 18(2):201-210.
86. E.S. Meadows, S.S. Johnston, Z. Cao, K.A. Foley, G.M. Pohl, J.A. Johnston, and S.D. Ramsey, Illness-associated productivity costs among women with employer-sponsored insurance and abstract: objective: determine lost work time and job attrition for incident breast cancer. Manuscript under review at Journal of Occupational and Environmental Medicine, 2009.